RYR1 and hereditary disease: The introduction of the S2843A mutation offers the potential for a once-in-a-lifetime prime editing treatment applicable to a wide range of patients with leaky RyR1 channels, paving the way for a cost-effective and accessible solution to a complex genetic disorder.